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exclusion of asymptomatic popliteal artery aneurysms are promising with few
complications and continue to match historical results with surgical arterial
reconstruction.
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Contemporary Management of Critical Lower Limb Ischaemia (CLI)
with TASC C and D femoro-popliteal lesions. 5-year Comparative
Trial of Subintimal Angioplasty (SIA) or Bypass surgery (BS)
Sherif Sultan, Niamh Hynes. Western Vascular Institute, Galway, Ireland
CLI patients face a dismal prognosis with one year mortality up to 30%
Infra-popliteal BS is a demanding procedure with poor long-term survival. A
minimally invasive therapy with equivalent results would be more appropri-
ate. SIA is easy to execute; requires short hospital admission and lower costs.
Primary endpoints are sustained clinical improvement (SCI) and amputation
free survival (AFS). Secondary endpoints are BinaryRrestenosis (BR) rate,
Freedom from target lesion revascularisation (TLR), risk of Major Adverse
Clinical Events (MACE), Quality Time Without Symptoms of disease or
Toxicity of Treatment (Q-TWiST) and cost-effectiveness. From 2002-
2007, 1076 patients were referred with PVD. 334 primary procedures
(SIA206, BS128) in 309 patients (NSIA190, NBS119) with TASC
C and D lesions were prospectively compared Mean age (SIA 73/13yrs
vs. BS 70/14yrs, p0.127), and co-morbidity severity scores (P0.05)
were similar between groups. 5-year SCI was 82.8% for SIA and 68.2% for
BS ( p0.106 h0.65, 95%CI[0.38-1.11]). 5-year all-cause survival was
similar for SIA (78.6%) and BS (80.1%), p0.7343. 5-year AFS was com-
parable (SIA 72.9% vs. BS 71.2%, p0.9765). Hyper-fibrinogenaemia and
elevated CRP had negative effect on AFS (p0.009, RR2.4, 95%CI1.2-
4.6 and p0.019, RR1.02, 95%CI1.01-1.04, respectively). 5-year free-
dom from BR were (SIA72.8% vs.BS65.3%, p0.7001). Hyper-homocys-
teine had significant adverse effect on risk of BR for SIA (p0.008) and BS
(p0.019) Results were not effected by stent use (35%, p0.780) or mean
number of stents (RR1.3, p0.330). 5-year freedom from TLR was (SIA
85.9% vs. BS 72.1%, p0.262). Risk of MAE (P0.002) and length of
hospital stay (LOSSIA14/16days vs. LOSBS24/23days,
P0.0001) were significantly reduced with SIA. Q-TWiST significantly
improved (P0.001) and cost per QALY (SIA: €5,663 vs BS: €9,172,
P0.05) reduced with SIA. 5-year risk of re-intervention (p0.05) and
mean number of procedures (SIA 1.19 vs. BS 1.10, p0.078) were similar.
BS is an independent risk factor for MACE. 5-year Freedom fromMACE in
SIA is enhanced by 20%. SIA enhances patient-specific Q-TWiST with
substantial cost reduction, is minimally invasive and allows for a high patient
turnover without compromising limb salvage. SIA has caused a Paradigm
Shift in CLI Management.
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PP34.
Inflow and Outflow Improvement by Endovascular Procedures During
Surgical Revascularization of Lower Limbs.
Gianluca Faggioli, Mauro Gargiulo, Natascia Muccini, Federica Giovanetti,
Antonio Freyrie, Andrea Stella. University of Bologna, Bologna, ItalyBackground: Endovascular revascularization techniques (ERT) are
increasingly performed in the treatment of critical limb ischemia (CLI),
however their role as an adjunct to open surgical revascularizations
(OSR), has been scarcely investigated, particularly as a method to im-
prove outflow. We have evaluated early and long-term results of CLI
revascularization obtained by OSR with either proximal or distal simul-
taneous ERT.
Methods: A series of consecutive patients undergoing simultaneous
OSR and ERT for CLI have been prospectively evaluated. Cases were
divided into three groups: GI: inflow procedures - ERT was performed
proximally to the proximal anastomosis of OSR; GII combined proce-
dures - profundoplasty and distal ERT; GIII - proximal OSR and distal
ERT. Choice for simultaneous ERT was made when a sufficient length of
autologous graft was unavailable or in order to significantly reduce the
magnitude of OSR. Results have been evaluated clinically and by duplex
scanning perioperatively and at 3, 6, 12, 18, 24 and 36 months and
calculated by life table analysis. Differences between groups were assessed
by log-rank test.
Results: In a series of 867 treatments for CLI, simultaneous OSR and
ERT were performed in 52 cases (5.9%) (GI: 23 - 44.2%, GII 11 - 21.1%,
and GIII 16 - 30.7%), with perioperative patency of 100%. Follow-up was
available in 50 cases (94%) for a mean of 11.5 8.8months. Overall patency
and survival at 36months were 59.5% and 79.6% respectively (GI: 74.1% and
70.8%, GII 60.6% and 90.9%, GIII 34.4% and 100%, p0.16 and 0.54
between groups).
Conclusions: Regardless of the strategy utilized, ERT are a valuable
adjunct to OSR and may help to minimize the impact of OSR. Early and
long-term results in cases with known unfavourable expectation are encour-
aging. Inflow and outflow ERT have similar impact on results.
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Assessment of Self-Expanding Nitinol Stent Deformations Implanted
into the Femoropopliteal Artery
Alexander Nikanorov1, Martin Schillinger2, Hugh Zhao1, Erich Minar2,
Lewis B Schwartz1. 1Abbott Vascular, Santa Clara, CA; 2Medical University
of Vienna, Vienna, Austria
Objectives: Endovascular stenting has emerged as a promising therapy
for femoropopliteal occlusive disease, but stent fractures remain a safety
concern. The aim of this study was to quantify the degree of deformations
encountered by nitinol stents when implanted into patients.
Methods: Patients undergoing femoropopliteal endovascular stenting
were eligible for study. Stent deformations were assessed by measurement of
stent length, deflection angle and bending radius via lateral view radiograms
obtained two days and six months following implantation with the patient in
three positions: neutral standing (knee/hip flexion 0°/0°), simulated am-
bulation (knee/hip flexion 70°/20°) and simulated stair climbing (knee/
hip flexion 90°/90°).
Results: Nineteen stent implantations in seventeen patients were
assessed. Stents were confined to the superficial femoral artery (SFA) in
eleven cases, extended to the proximal popliteal artery (SFA/prox pop)
in two cases (defined as terminating at least 3 cm above the intercondylar
fossa) and crossed the knee joint (popliteal) in six cases. Single stents of
80 or 100 mm length were implanted in sixteen cases; overlapped stents
were required in three cases. Leg flexion was associated with 5-10%
shortening (compression) of the stent, the greatest amount being ob-
served for stents implanted into the popliteal artery (SFA 3.1%1.8%,
SFA/prox pop 5.30.5%, popliteal 8.6%3.2%). Profound stent bend-
ing (deflection angle 64°16°, bending radius 222 mm) was observed
in the popliteal artery, with slight bending in the SFA stents (SFA 5°2°,
13853 mm; SFA/prox pop 8°4°, 5510 mm). Follow-up examina-
tions were performed in fourteen stent implantations of thirteen patients
after a mean follow-up of 7.11.3 months. In these patients, the degree
of stent deformation during leg flexion was essentially unchanged as
compared to immediate post-procedure levels.
Conclusions: In patients with femoropopliteal occlusive disease, in-
dwelling nitinol stents are routinely bent and compressed during leg flexion.
Stent bending is considerably more pronounced after implantation into the
popliteal artery as compared to the SFA. As the observed levels of compres-
sion and bending were unchanged after six months, short-term vascular
remodeling appears to have no effect on stent deformation.
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